Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Movement Disorders » Dyskinesias » Dyskinesia, Drug-Induced » Tardive Dyskinesia
Diseases [C] » Nervous System Diseases [C10] » Neurologic Manifestations » Dyskinesias » Dyskinesia, Drug-Induced » Tardive Dyskinesia
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Signs and Symptoms » Neurologic Manifestations » Dyskinesias » Dyskinesia, Drug-Induced » Tardive Dyskinesia
Description
Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE). MeSH
Hierarchy View
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (4)
Phase 3 Indicated Drugs (4)
Phase 2 Indicated Drugs (2)
Other Experimental Indicated Drugs (1)
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (10)
Organization Involved with Other Experimental Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
